Trial Profile

A Randomized, Double-blind, Multicenter Study to Determine the Effect of Triheptanoin Compared with Even-chain, Medium-chain Triglycerides (MCT) on Major Clinical Events (MCEs) in Pediatric Patients with Long-chain Fatty Acid Oxidation Disorders (LC-FAOD )

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 04 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Triheptanoin (Primary) ; Triheptanoin (Primary) ; Medium-chain triglyceride; Medium-chain triglyceride
Indications Lipid metabolism disorders
Focus Registrational; Therapeutic Use
Sponsors Ultragenyx Pharmaceutical

25 Feb 2025 Status changed to recruiting.
10 Feb 2025 Planned End Date changed from 1 Sep 2026 to 1 Aug 2027.
10 Feb 2025 Planned primary completion date changed from 1 Sep 2026 to 1 Aug 2027.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com